SCHOTT Pharma
€24.55Change from previous close: +0.82%Absolute change: +€0.20
At a glance
- Revenue growth
- +3.04%
- FY to Sep 2025 vs FY to Sep 2024
- Net income growth
- −2.16%
- FY to Sep 2025 vs FY to Sep 2024
- Net margin
- 14.9%
- FY to Sep 2024: 15.6%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 282 | 248 | 240 | 248 | 256 | — |
| Cost of revenue | 195 | 173 | 160 | 172 | 160 | — |
| Gross profit | 86.4 | 75.1 | 79.8 | 76.1 | 95.9 | — |
| Selling, general and administrative | 35.3 | 32.5 | 33.7 | 32.1 | 32.2 | — |
| Research and development | 6.3 | 6.0 | 7.3 | 6.4 | 7.3 | — |
| Operating income | 48.9 | 39.5 | 39.0 | 41.4 | 60.0 | — |
| EBIT | 55.1 | 44.3 | 46.0 | 47.2 | 64.9 | — |
| EBITDA | 77.3 | 66.2 | 67.5 | 69.3 | 84.6 | — |
| Interest expense | 3.9 | 4.0 | 4.0 | 5.5 | 4.9 | — |
| Pre-tax income | 51.2 | 40.3 | 42.0 | 41.8 | 60.0 | — |
| Income tax | 12.2 | 9.2 | 8.8 | 8.1 | 14.4 | — |
| Net income | 38.8 | 31.0 | 33.2 | 33.6 | 45.4 | — |
| Net income to common shareholders | 38.8 | 31.0 | 33.2 | 33.6 | 45.4 | — |
| Basic EPS | 0.26 | 0.21 | 0.22 | — | 0.30 | 0.25 |
| Diluted EPS | 0.26 | 0.21 | 0.22 | — | 0.30 | 0.25 |
| Average shares (basic) | 149 | 148 | 151 | — | 151 | 153 |
| Average shares (diluted) | 149 | 148 | 151 | — | 151 | 153 |